ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases.
The last earnings update was 49 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
ARCA biopharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
ARCA biopharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
ARCA biopharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if ARCA biopharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
ARCA biopharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Michael R. Bristow, M.D., Ph.D., co-founded ARCA Biopharma, Inc. (formerly known as, ARCA Discovery, Inc.) in September 2004 and has been its Chief Executive Officer and President since July 10, 2009. Previously, Dr. Bristow served as the President and Chief Executive Officer of ARCA biopharma, Inc. from September 2004 to November 2006. Mr. Bristow served as the Chief Science & Medical Officer of ARCA biopharma, Inc. from November 6, 2006 to July 10, 2009. He founded Gilead Colorado, Inc. and was its Scientific Advisor since February 2006. Mr. Bristow is the Professor of Medicine at the University of Colorado. He co-founded miRagen Therapeutics, Inc. in 2006. Dr. Bristow was one of the founders of Myogen, Inc. He served as Chief Science and Medical Officer of Myogen Inc. from October 1996 to February 2006. He served as Scientific Advisor to Myogen from February 2006 to November 2006. Mr. Bristow served as the Head of Cardiology at the University of Colorado Health Sciences Center and Co-Director of the University of Colorado Cardiovascular Institute. He served as the Chairman at ARCA biopharma, Inc. from November 6, 2006 to July 10, 2009. He was a Director of Gilead Colorado, Inc. (a/k/a Myogen Inc.) since October 1996. He has been a Member of Scientific Advisory Board of miRagen Therapeutics, Inc. since January 2010. He has been a Director of ARCA biopharma, Inc. since January 2009. He served as a Member of Scientific Advisory Board at Nile Therapeutics, Inc. since October 2010. Mr. Bristow served as a Member of the Scientific Advisory Board of Inverseon Inc. He is the author of over 300 peer-reviewed publications and chapters on heart failure or cardiomyopathy for cardiology textbooks, including Braunwald's "Heart Disease: A Textbook of Cardiovascular Medicine" and Hurst's "The Heart." Mr. Bristow holds an M.D. and Ph.D. from the University of Illinois.
Michael's compensation has been consistent with company performance over the past year, both up more than 20%.
Michael's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the ARCA biopharma management team is over 5 years, this suggests they are a seasoned and experienced team.
Chief Operating Officer
Chief Accounting Officer & VP of Finance
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the ARCA biopharma board of directors is about average.
Board of Directors
Independent Chairman of the Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.